natgillin/translations-raw huggingface dataset:
The field studies showed that Equip WNV protects horses from West Nile virus by reducing the number of viraemic horses after infection with West Nile virus lineage 1 or 2 strains and by reducing the duration and severity of clinical signs against lineage 2 strains.
Terenska ispitivanja su pokazala da Equip WNV štiti konje od virusa Zapadnog Nila tako što smanjuje broj viremičnih konja nakon infekcije virusom Zapadnog Nila, linije sojeva 1 ili 2 te smanjuje trajanje i težinu kliničkih znakova linije sojeva 2.
The field studies showed that Suvaxyn Circo+MH RTU reduced the PCV2 viraemia (presence of virus in the blood) compared to pigs given dummy vaccination.
Terenska su ispitivanja pokazala da je Suvaxyn Circo+MH RTU smanjio viremiju virusa PCV2 (prisutnost virusa u krvi) u usporedbi sa svinjama kojima je dano lažno cjepivo.
The field studies showed that vaccination with Porcilis PCV M Hyo reduced PCV2 levels in the blood and the severity of lung lesions caused by Mycoplasma hyopneumoniae and the loss of daily weight gain during the finishing period (the fattening period prior to slaughter).
Terenska ispitivanja pokazala su da je cijepljenje cjepivom Porcilis PCV M Hyo smanjilo razine PCV2 u krvi i težinu lezija pluća uzrokovanih bakterijom Mycoplasma hyopneumoniae te gubitak dnevnog porasta težine tijekom razdoblja završnog tovljenja (razdoblje tovljenja prije klanja).
The field studies to investigate the efficacy of the vaccine were done in herds where persistently infected animals had been removed.
Terenska ispitivanja za dokazivanje djelotvornosti cjepiva provedena su na stadima iz kojih su uklonjene trajno zaražene životinje.
The field studies were carried out on a large number of farms in various European countries involving various breeds and crossbreeds of pigs.
Terenska ispitivanja provedena su na velikom broju farmi u različitim europskim zemljama uključujući i različite pasmine i hibride svinja.
The field study for gut worms showed that Nexgard Spectra was effective in reducing gut worms and was at least as effective as the milbemycin oxime and praziquantel.
Terenskim ispitivanjem za gastrointestinalne crve utvrđeno je da je VMP Nexgard Spectra bio podjednako djelotvoran u smanjivanju crva te da je bio barem podjednako djelotvoran kao milbemicin oksim i prazikvantel.
The field study involved 129 cats with flea infestations that were treated once a month for three consecutive months either with Vectra Felis or with another spot-on product containing two different substances, fipronil and (S)-methoprene, that control fleas.
Terensko je ispitivanje obuhvatilo 129 mačaka s infestacijama buhama koje su liječene jednom tijekom tri uzastopna mjeseca lijekom Vectra Felis ili drugim lijekom za nakapavanje koji sadrži dvije različite supstance, fipronil i (S)-metopren koje kontroliraju buhe.
The field study showed that Bravecto was effective in reducing the number of fleas and ticks in dogs with existing flea or tick infestations and that its effects against fleas and most tick species persisted for 3 months.
Terenskim je ispitivanjem utvrđeno da je VMP Bravecto djelotvoran u smanjivanju broja buha i krpelja u pasa s postojećim infestacijama buhama ili krpeljima te da je njegovo djelovanje protiv buha i većine vrsta krpelja trajalo tijekom 3 mjeseca.
The field study showed that Vectra Felis was as effective as the comparator product and reduced flea counts by 91% over the 84 day study period.
Terensko ispitivanje lijeka Vectra Felis pokazalo se podjednako djelotvornim kao komparatorski veterinarsko-medicinski proizvod i smanjio je broj buha za 91% tijekom razdoblja ispitivanja od 84 dana.
The fifth patient, who had pre-existing cardiopathy, was diagnosed with ventricular premature complexes and pulmonary embolism during the study.
Petom bolesniku, kod kojeg je već postojala kardiopatija, tijekom ispitivanja dijagnosticirani su preuranjeni ventrikularni kompleksi i plućna embolija.
The figure for the combination treatment of Viread and emtricitabine was 88%.
Vrijednost za kombinirano liječenje lijekom Viread i emtricitabinom iznosila je 88%.
The figure was 85% in the patients who received the 15-microgram dose.
Brojka je iznosila 85% u bolesnika koji su primali dozu od 15 mikrograma.
The figures are based on how many people said they’d had them.
Brojevi su temeljeni na tome koliko je osoba izjavilo da ih imaju.
The figures are based on how many people said they’d had them.
Brojevi su temeljeni na tome koliko je osoba izjavilo da ima nuspojavu.
The filgrastim in Accofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim.
Filgrastim u lijeku Accofil proizvodi se metodom „tehnologije rekombinatne DNK”: proizvodi ga bakterija u čiji gen (DNK) je umetnut filgrastim.
The filgrastim in Grastofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim.
Filgrastim u lijeku Grastofil stvara se metodom poznatom pod nazivom „tehnologija rekombinantne DNK”: proizvodi se od bakterije u koju je ugrađen gen (DNK) koji omogućava stvaranje filgrastima.
The filgrastim in Lonquex is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes the bacteria able to produce the filgrastim protein.
Filgrastim u lijeku Lonquex proizvodi se metodom pod nazivom „tehnologija rekombinantne DNA”: proizvode ga bakterije u koje je unesen gen (DNK) koji im omogućuje proizvodnju bjelančevine filgrastima.
The film coat of the tablet contains polyvinyl alcohol, titanium dioxide (E171), macrogol, talc and yellow iron oxide (E172).
Film ovojnica tablete sadrži poli(vinilni alkohol), titanijev dioksid (E171), makrogol, talk i žuti željezov oksid (E172).
The film coating contains: hypromellose (E464), titanium dioxide (E171), macrogol 400, yellow iron oxide (E172), and carnauba wax.
Film ovojnica sadrži: hipromelozu (E464), titanijev dioksid (E171), makrogol 400, žuti željezov oksid (E172) i karnauba vosak.
The film- coated tablets can be taken with or without food.
Filmom obložene tablete mogu se uzimati sa ili bez hrane.
The film-coated tablet (tablet) is a, oval, biconvex, brick red coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/40 on one side and the Abbott logo  on the other side.
Filmom obložena tableta (tableta) je ovalna, bikonveksna, ciglasto crvena tableta veličine 19,3 x 9,3 mm s kosim rubovima i oznakom 145/40 na jednoj strani i logotipom Abbott  na drugoj strani.
The film-coated tablet (tablet) is a, oval, biconvex, tan coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/20 on one side and the Abbott logo  on the other side.
Filmom obložena tableta (tableta) je ovalna, bikonveksna, žućkastosmeđa tableta veličine 19,3 x 9,3 mm s kosim rubovima i oznakom 145/20 na jednoj strani i logotipom Abbott  na drugoj strani.
The film-coated tablet is oval-shaped, green, marked with "144" on one side.
Filmom obložena tableta je ovalna, zelena, s oznakom "144" na jednoj strani.
The film-coated tablet is oval-shaped, pink, marked with "227" on one side.
Filmom obložena tableta je ovalna, ružičasta, s oznakom "227" na jednoj strani.
The film-coated tablet should not be chewed, crushed, or split.
Filmom obloţena tableta ne smije se ţvakati, drobiti ili lomiti.
The film-coated tablets (tablets) are white to off white, oblong, convex, embossed ‘15 / 850’ on one face and ‘4833M’ on the other.
Filmom obložene tablete (tablete) su bijele do gotovo bijele boje, ovalne, konveksne s utisnutim „15 / 850“ na jednoj strani i „4833M“ na drugoj.
The film-coated tablets are beige, oval, debossed with “770” on one side and plain on the other.
Filmom obložene tablete su ovalne bež tablete, s utisnutom oznakom "770" na jednoj strani i bez oznake na drugoj strani.
The film-coated tablets are light peach colored, oblong shaped, biconvex, 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side.
Filmom obložene tablete su duguljaste, bikonveksne, svijetle boje breskve, duljine 11,4 mm i širine 5,3 mm s utisnutom oznakom ''150'' s jedne strane i bez oznake na drugoj strani.
The film-coated tablets are light peach tablets of biconvex, oblong shape with the marking ‘150’ on the one side and ‘Xeloda’ on the other side
Filmom obložene tablete su bikonveksne, duguljaste tablete svijetle boje breskve, s oznakom ''150'' s jedne strane i ''Xeloda'' s druge strane.
The film-coated tablets are light pink to pink, film coated, capsule shaped tablets.
Filmom obložene tablete su svijetloružičaste do ružičaste filmom obložene tablete u obliku kapsula.
The film-coated tablets are modified capsule-shaped, pale yellow to light-tan and debossed with ‘FX75’ on one side.
Filmom obložene tablete su modificiranog oblika kapsule, blijedožute do svijetlosmeđe s utisnutom oznakom „FX75“ na jednoj strani.
The film-coated tablets are modified capsule-shaped, pink-orange to peach and debossed with ‘FX100’ on one side.
Filmom obložene tablete su modificiranog oblika kapsule, ružičasto-narančaste boje do boje breskve s utisnutom oznakom „FX100“ na jednoj strani.
The film-coated tablets are not breakable and are to be swallowed whole, with water.
Filmom obložene tablete ne mogu se lomiti i treba ih progutati cijele s vodom.
The film-coated tablets are of oblong shape and white to off-white in colour, engraved L2/IT.
Bondronat filmom obložene tablete ovalnog su oblika i bijele do bjelkaste boje, a na njima je utisnuto L2/IT.
The film-coated tablets are orange, diamond-shaped tablets debossed with “GSI” on one side and “7985” on the other side.
Filmom obložene tablete narančaste su tablete u obliku dijamanta, s utisnutim “GSI” na jednoj strani i “7985” na drugoj strani.
The film-coated tablets are peach tablets of biconvex, oblong shape with the marking ‘500’ on the one side and ‘Xeloda’ on the other side.
Filmom obložene tablete su bikonveksne, duguljaste tablete boje breskve, s oznakom ''500'' s jedne strane i ''Xeloda'' s druge strane.
The film-coated tablets are pink, oval-shaped tablets, debossed on one side with “GSI” and “150” on the other side.
Filmom obložene tablete su ružičaste, ovalne tablete s utisnutom oznakom “GSI” s jedne i “150” s druge strane.
The film-coated tablets are pink, round and biconvex.
Filmom obložene tablete su ružičaste, okrugle i bikonveksne.
The film-coated tablets are pink, round and slightly convex.
Filmom obložene tablete su ružičaste, okrugle i blago ispupčene.
The film-coated tablets are pink, round and slightly convex.
Filmom obložene tablete su ružičaste, okrugle i blago konveksne.
The film-coated tablets are pink, round and slightly convex.
Filmom obložene tablete su ružičaste, okrugle i blago zaobljene.
The film-coated tablets are pink, round and slightly convex.
Ružičaste, okrugle blago ispupčene filmom obložene tablete.
The film-coated tablets are provided in bottles containing 30 or 90 tablets.
Filmom obložene tablete dolaze u bočicama koje sadrže 30 ili 90 tableta.
The film-coated tablets are supplied in opaque white plastic bottles with threaded plastic closures.
Filmom obložene tablete dolaze u bijelim neprozirnim plastičnim bocama s plastičnim zatvaračima s navojem.
The film-coated tablets are white to off white, oblong shaped, biconvex, 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side.
Filmom obložene tablete su duguljaste, bikonveksne, svijetle boje breskve, duljine 14,6 mm i širine 6,7 mm s utisnutom oznakom ''300'' s jedne strane i bez oznake na drugoj strani.
The film-coated tablets are white, round biconvex tablets supplied in Polyamide/Al/PVC - Aluminum foil blister.
Filmom obložene tablete bijele su i okrugle bikonveksne tablete i isporučuju se u blister pakovanju (poliamid/Al/PVC – aluminijska folija).
The film-coated tablets are white, round biconvex tablets supplied in Polyamide/Al/PVC - Aluminum foil blister.
Filmom obložene tablete su bijele, okrugle, bikonveksne tablete pakirane u blistere od poliamid/Al/PVC - aluminijske folije.
The film-coated tablets consist of a core tablet, surrounded by a film coating to prevent exposure of health care professionals to the active substance.
Filmom obložene tablete se sastoje od jezgre tablete obložene film ovojnicom kako bi se spriječilo izlaganje zdravstvenih radnika djelatnoj tvari.
The film-coated tablets must not be crushed or cut in order to minimize the risk of dermal exposure, they must be swallowed whole.
Filmom obložene tablete se ne smiju drobiti niti rezati, kako bi se smanjio rizik dodira s kožom, nego se moraju progutati cijele.
The film-coated tablets should be swallowed whole Read the package leaflet before use
Filmom obložene tablete treba progutati cijele Prije uporabe pročitajte Uputu o lijeku
The film-coating consists hypromellose, macrogols (8000), titanium dioxide (E171), talc and ferric oxide red (E172).
Film -ovojnica sastoji se od hipromeloze, makrogola (8000), titanijevog dioksida (E171), talka i crvenog željezovog oksida (E172).
The film-coating contains hypromellose, polysorbate 80, glycerol 85%, sucrose, yellow iron oxide (E172), red iron oxide (E172) and titanium dioxide (E171), magnesium stearate.
Ovojnica tablete sadrži hipromelozu, polisorbat 80, glicerol 85%, saharozu, žuti željezov oksid (E 172), crveni željezov oksid (E 172), titanijev dioksid (E 171) i magnezijev stearat.
The film-coating contains partly hydrolysed polyvinyl alcohol, talc, macrogol, soybean lecithin, yellow iron oxide (E 172), red iron oxide (E 172) and titanium dioxide (E 171).
Ovojnica tablete sadrži polivinilni alkohol, djelomično hidroliziran, talk, makrogol, sojin lecitin, žuti željezov oksid (E 172), crveni željezov oksid (E 172) i titanijev dioksid (E 171).
The film-coating contains partly hydrolysed polyvinyl alcohol, talc, macrogol, soybean lecithin, yellow iron oxide (E 172), red iron oxide (E 172) and titanium dioxide (E 171).
Ovojnica tablete sadrži polivinilni alkohol, djelomično hidroliziran, talk, makrogol, sojin lecitin, žuti željezov oksid (E172), crveni željezov oksid (E172) i titanijev dioksid (E171).
The film-coating contains poly(vinyl alcohol) - partially hydrolysed, macrogol 3350, titanium dioxide (E171), talc, sunset yellow FCF (E110).
Film-ovojnica sadrži poli(vinilni alkohol) - djelomično hidroliziran, makrogol 3350, titanijev dioksid (E171), talk, boja sunset yellow FCF (E110).
The film-coating contains polyvinyl alcohol, titanium dioxide (E171), - macrogol, talc, iron oxide red (E172).
Film-ovojnica sadrži poli(vinilni alkohol), titanijev dioksid (E171) - makrogol, talk, željezov oksid, crveni (E172).
The film-coating contains soya lecithin.
Film kojim su obložene tablete sadrži sojin lecitin.
The film-coating contains soya lecithin.
omaglica akatizija6 parkinsonizam6 diskinezija6
The film-coating contains: 250 mg: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc
Film ovojnica sadrži: 250 mg: poli(vinilni alkohol), titanijev dioksid (E171), makrogol, talk
The film-coating of each 10 mg tablet contains 0.24 mg soya lecithin.
Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS)
The film-coating of each 15 mg tablet contains 0.15 mg soya lecithin.
Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS)
The film-coating of each 20 mg tablet contains 0.20 mg soya lecithin.
Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS)
The filter should be removed from the blister pack, and the cap removed from the filter spike.
Filtar treba izvaditi iz blister pakiranja i s njegovog šiljka skinuti kapicu.
The filter should be removed from the blister pack, and the cap removed from the filter spike.
Filtar treba izvaditi iz blistera i s njegovog šiljka skinuti kapicu.
the final
završnog
The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.
Preostala 1/3 primijenjene doze izlučuje se izravno putem bubrega u mokraću u obliku nepromijenjene djelatne tvari, pretežno aktivnom bubrežnom sekrecijom.
The final [90Y]-radiolabelled Zevalin solution contains up to 28 mg sodium per dose, depending on the radioactivity concentration.
Konačna otopina Zevalina radioaktivno označenog izotopom [90Y], ovisno o koncentraciji radioaktivnosti, sadrži do 28 mg natrija po dozi.
The final analysis confirmed that R-CHOP
Završna analiza potvrdila je da je liječenje
The final analysis showed no significant difference with a median survival follow-up of 21.2 months resulted in a median of 13.7 months (95% CI: 12.2, 16.0) for the trabectedin arm and 13.1 months [95% CI: 9.1, 16.2] for the dacarbazine arm.
Završna analiza nije pokazala značajnu razliku u medijanu preživljenja u razdoblju praćenja od 21,2 mjeseca koji je rezultirao medijanom od 13,7 mjeseci (95% CI: 12,2; 16,0) za skupinu s trabektedinom i medijanom od 13,1 mjesec [95% CI: 9,1; 16,2] za skupinu s dakarbazinom.
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow- up before).
Konačna analiza provedena je nakon što su svi bolesnici dosegli 10 godina praćenja (osim ako ranije nisu imali DFS događaj ili su ranije prestali biti praćeni).
The final analysis will be performed when at least 40 patients identified with RET mutation and 40 patients identified without evidence of RET mutation have been enrolled into the study and received vandetanib for 14 months.
Konačna analiza provest će se nakon što je najmanje 40 bolesnika s utvrđenom RET mutacijom i 40 bolesnika bez dokaza RET mutacije uključeno u ispitivanje i primalo vandetanib tijekom 14 mjeseci.
The final clinical study report should be submitted by 31st March 2017
Završno izvješće o kliničkom ispitivanju potrebno je predati do
The final clinical study report should be submitted by 31st October 2016
Završno izvješće o kliničkom ispitivanju potrebno je predati do
The final clinical study report should be submitted by:
Završno izviješće kliničkog ispitivanja mora se podnijeti do:
The final concentration of Defitelio should be in the concentration range of 4 mg/mL – 20 mg/mL (see section 6.3).
Konačna koncentracija lijeka Defitelio mora biti u koncentracijskom rasponu od 4 mg/mL do 20 mg/mL (vidjeti dio 6.3).
The final concentration of Defitelio should be in the range of 4 mg/mL to 20 mg/mL.
Konačna koncentracija lijeka Defitelio mora biti u rasponu od 4 mg/mL do 20 mg/mL.
The final concentration of the skimmed milk powder should be 5 g/l.
Konačna koncentracija obranog mlijeka u prahu treba biti 5 g/L.
The final concentration of the skimmed milk powder should be 5 g/litre.
Konačna koncentracija obranog mlijeka u prahu treba biti 5 g/L.
The final diluted solution in the bag or bottle should be inspected visually for particulate matter and discolouration prior to administration.
Dobivenu otopinu u vrećici ili bočici prije primjene treba vizualno pregledati da ne sadrži čestice i nije promijenila boju.
The final formulation after radiolabelling contains 2.08 mg [90Y] ibritumomab tiuxetan in a total volume of 10 ml.
Konačna formulacija nakon radioaktivnog označavanja sadrži 2,08 mg [90Y] ibritumomab tiuksetana u ukupnom volumenu od 10 ml.
The final formulation after radiolabelling contains 2.08 mg ibritumomab tiuxetan [90Y] in a total volume of 10 ml.
Konačna formulacija nakon radioaktivnog označavanja sadrži 2,08 mg ibritumomab tiuksetana [90Y] u ukupnom volumenu od 10 ml.
The final OS analysis (12 January 2015) demonstrated a statistically significant improvement in OS for the combination compared with dabrafenib monotherapy (Figure 1).
Konačna OS analiza (12. siječnja 2015.) je pokazala statistički značajno poboljšanje u OS-u za kombinaciju u usporedbi s monoterapijom dabrafenibom (slika 1).
The final radiolabelled injection solution must be protected from oxygen.
Konačnu radioaktivno obilježenu otopinu za injekcije potrebno je zaštititi od kisika.
The final report is expected in Q1 2018.
Konačno izvješće očekuje se u prvom kvartalu 2018.
The final solution must be inspected visually for particulate matter before administration.
Konačnu otopinu treba vizualno pregledati prije primjene da ne sadrži sitne čestice.
The final solution should be infused over 30 minutes.
Konačno pripremljenu otopinu treba primijeniti infuzijom tijekom 30 minuta.
The final solution should be inspected visually for fine particles before administration.
Konačnu otopinu treba vizualno pregledati prije primjene da ne sadrži sitne čestice.
The final study
izvješće
The final study compared Reyataz plus either ritonavir or saquinavir with ritonavir-boosted lopinavir in 358 patients.
U posljednjem je ispitivanju provedenom na 358 bolesnika Reyataz uz istodobnu primjenu ritonavira ili sakvinavira uspoređen s lopinavirom ojačanim ritonavirom.
The final study report shall be submitted by
Konačno izvješće o ispitivanju bit će podneseno do
The final suspension containing the vaccine should be consumed within 4 hours after preparation.
Posljednja suspenzija koja sadrži cjepivo treba se potrošiti u roku od 4 sata nakon pripreme.
The final volume in the infusion bag should be 250 mL.
Konačni volumen u infuzijskoj vrečići treba biti 250 ml.
The final volume is approximately 11.4 mL.
Konačni volumen iznosi približno 11,4 ml.
The final volume of a 5 mg/ml diluted solution is 60 ml for 300 mg doses, 120 ml for 600 mg doses, 180 ml for 900 mg doses and 240 ml for 1,200 mg doses.
Konačni volumen razrijeđene otopine od 5 mg/ml iznosi 60 ml za doze od 300 mg, 120 ml za doze od 600 mg, 180 ml za doze od 900 mg i 240 ml za doze od 1200 mg.
The findings were observed at approximately the recommended dose in rats and 6 times the recommended dose in dogs (AUC basis).
Nalazi su primijećeni kod otprilike preporučene doze u štakora i 6 puta preporučene doze kod pasa (na temelju AUC).
The first 18 weeks of treatment is a critical period which requires close monitoring (see section 4.4).
Prvih 18 tjedana liječenja predstavljaju kritično razdoblje koje zahtijeva pomno praćenje (vidjeti dio 4.4).
The first 18 weeks of treatment is a critical period which requires close monitoring (see section 4.4).
Prvih 18 tjedana liječenja predstavljaju kritično razdoblje koje zahtijeva pomno praćenje (vidjeti dio 4.4.).
The first 18 weeks of treatment is a critical period which requires close monitoring (see section 4.4).
Prvih 18 tjedana liječenja predstavljaju kritično razdoblje koje zahtijeva pomno praćenje (vidjeti točku 4.4).
The first 2 patients enrolled received a dose of 3 x 1011 gc/kg, the next 4 patients received a dose of 3 x 1011 gc/kg with immunosuppressant regiment (oral ciclosporin and oral mycophenolate mofetil from the day after Glybera administration until Week 12) and the final 8 patients received a dose of 1 x 1012gc/kg with immunosuppressant regiment.
Prva 2 bolesnika uključena u ispitivanje primila su dozu od 3 x 1011 gk/kg, sljedeća 4 bolesnika primila su dozu od 3 x 1011 gk/kg s imunosupresivnom terapijom (peroralni ciklosporin i peroralni mofetilmikofenolatom počevši od dana nakon injiciranja Glybere do 12. tjedna), a zadnjih 8 bolesnika primilo je dozu od 1 x 1012gk/kg s imunosupresivnom terapijom.
The first 330 patients were centrally assessed (response rate 6.2%); 401 patients were investigator- assessed (response rate 11.2%).
U prvih 330 bolesnika procjenu stope odgovora provelo je neovisno centralno povjerenstvo (stopa odgovora od 6,2%), dok je u preostalih 401 bolesnika stopu odgovora ocijenio ispitivač (stopa odgovora od 11,2%).
The first administration of Cetrotide should be performed under the supervision of a physician and under conditions where treatment of possible allergic/pseudo-allergic reactions (including life- threatening anaphylaxis) is immediately available.
Prvu primjenu lijeka Cetrotide treba provesti pod nadzorom liječnika i u uvjetima u kojima je odmah dostupno liječenje mogućih alergijskih/pseudoalergijskih reakcija (uključujući i po život opasne anafilaksije).